Glecaprevir–pibrentasvir for chronic hepatitis C: Comparing treatment effect in patients with and without end-stage renal disease in a real-world setting

INTRODUCTION: Chronic hepatitis C virus (HCV) infection is increasingly observed in patients with renal disease. With the introduction of glecaprevir/pibrentasvir (GLE/PIB) as a pan-genotype therapy for HCV, treatment efficacy is expected to rise. MATERIALS AND METHODS: This retrospective study eval...

Descripción completa

Detalles Bibliográficos
Autores principales: Yen, Hsu-Heng, Su, Pei-Yuan, Zeng, Ya-Huei, Liu, I-Ling, Huang, Siou-Ping, Hsu, Yu-Chun, Chen, Yang-Yuan, Yang, Chia-Wei, Wu, Shun-Sheng, Chou, Kun-Ching
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2020
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425913/
https://www.ncbi.nlm.nih.gov/pubmed/32790715
http://dx.doi.org/10.1371/journal.pone.0237582

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7425913/
https://www.ncbi.nlm.nih.gov/pubmed/32790715
http://dx.doi.org/10.1371/journal.pone.0237582

Ejemplares similares